Anti-MARV Envelope glycoprotein (GP) Human IgG ELISA Kit

Catalog No.

KAV24301

Specificity

Anti-Lake Victoria marburgvirus (MARV) Envelope glycoprotein (GP) Human IgG Antibody

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

1.56 - 100 ng/mL

Sensitivity

1.19 ng/mL

Precision

CV<15%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design., PMID:39285186

Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection., PMID:38158300

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine., PMID:36774693

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs., PMID:36423030

Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials., PMID:36298451

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates., PMID:36016226

Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay., PMID:36016099

Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses., PMID:34484200

Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation., PMID:30723475

Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease., PMID:30285648

Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge., PMID:29142131

Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses., PMID:28724616

Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques., PMID:28402024

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)., PMID:27070636

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges., PMID:25996997

Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays., PMID:25230936

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates., PMID:24759889

Serological evidence of Ebola virus infection in Indonesian orangutans., PMID:22815803

Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever., PMID:22253531

Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies., PMID:20861331

Document Download

Anti-MARV Envelope glycoprotein (GP) Human IgG ELISA Kit.pdf